Appeals court says drugmakers need HHS approval for a 340B rebate model
Issue
On July 21, 2026, the federal appeals court in D.C. Ruled that Novartis and Johnson & Johnson cannot replace up-front 340B discounts with rebates unless the HHS Secretary approves, the American Hospital Association reported. The ruling keeps the up-front discounts that health centers and their contract pharmacies rely on.
HHS could still approve a rebate model later.
Sources for this story
American Hospital Association (reporting the D.C. Circuit ruling)Part of
- 340B drug pricing
HRSA's rebate model pilot
Sources for your board packet
This story's source plus 4 related stories and their sources, ready to print for your team or board.
Free. Unlocking the packet subscribes you to Intel Brief. You'll also get a short welcome series and the occasional product update. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.
More in Funding & Budget
FQHC Talent. (2026, July 21). Appeals court says drugmakers need HHS approval for a 340B rebate model. Source: American Hospital Association (reporting the D.C. Circuit ruling). Retrieved November 11, 2026, from https://www.fqhctalent.com/intel/dc-circuit-340b-rebate-model-hhs-approval-july-2026